IOBT Stock IO Biotech (IOBT, $0.95) entered Uptrend as Momentum indicator ascends above 0 level on Jan 24, 2025
at Tickeron.com
IOBT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for IOBT turned positive on February 18, 2025. Looking at past instances where IOBT's MACD turned positive, the stock continued to rise in of 30 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on February 13, 2025. You may want to consider a long position or call options on IOBT as a result. In of 69 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
IOBT moved above its 50-day moving average on January 22, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IOBT crossed bullishly above the 50-day moving average on January 24, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IOBT advanced for three days, in of 146 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 72 cases where IOBT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IOBT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IOBT broke above its upper Bollinger Band on February 19, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.999) is normal, around the industry mean (12.481). P/E Ratio (0.000) is within average values for comparable stocks, (84.012). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.602). IOBT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (250.738).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IOBT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IOBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
General Information
Industry Biotechnology